Trial reportBMC neurology2026
Impact of MIND diet on cognitive function among patients with metabolic syndrome: a randomised control clinical trial.
Trial report in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundMediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet is a new dietary approach designed to help maintain cognitive function. Patients with MetS are at increased risk of cognitive decline due to chronic inflammation, oxidative stress, and vascular dysfunction. Therefore, this population provides an appropriate model to investigate the potential neuroprotective effects of the MIND diet, which emphasizes foods with anti-inflammatory and antioxidant properties.
aimsThis study aims to investigate the impact of this diet on the cognitive function of patients with MetS.
methodsThis research was a RCTs conducted with adults diagnosed with MetS who were referred to the Hazrat Ali Health Center in Isfahan. A total of 56 eligible participants were divided into two groups: one group received the MIND diet along with a placebo, while the other served as a control group. Statistical analysis was performed using SPSS26.
resultsIn this study, we compared the two groups. The MIND diet group showed a significant increase in total cognitive function after adjusting for Model 1 [Using Generalized Linear Model (GLM) with distribution of Gamma & link of Log controlling for baseline, gender, education, surgery, drug, supplementation, physical activity, age, and hospitalization] and 2 [Using Generalized Linear Model (GLM) with distribution of Gamma & link of Log controlling for baseline, gender, education, surgery, drug, supplementation, physical activity, age, hospitalization, and food intake], with increases of 1.6 times (60%) and 1.52 times (52%), respectively. In terms of visuoconstruction and executive functioning, there was a significant increase after adjusting for model 1 (1.42 times or 42%). Attention also significantly improved after adjusting models 1 and 2 by 2.05 times and 2.0 times, respectively. DISCUSSION: The antioxidant and anti-inflammatory properties of certain foods included in the MIND diet are believed to protect brain function and reduce cognitive decline like: Green leafy vegetables, berries, nuts, whole grains, and fish.
conclusionThis study suggests that MIND diet can significantly enhance total cognitive function, attention, executive functioning, and visuoconstruction abilities. REGISTRATION: The protocol for this study was also approved by the Iranian Registry of Clinical Trials on March 28, 2023, with registration reference IRCT20230105057054N1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.